Details der Publikation - The TRISTARDS trial - ThRombolysIS Therapy for ARDS A study to test whether different doses of alteplase help people with severe breathing problems because of COVID 19.

The TRISTARDS trial - ThRombolysIS Therapy for ARDS A study to test whether different doses of alteplase help people with severe breathing problems because of COVID 19. : The TRISTARDS trial - ThRombolysIS Therapy for ARDSA Phase IIb/III operationally seamless, open-label, randomised, sequential, parallel-group adaptive study to evaluate the efficacy and safety of daily intravenous alteplase treatment given up to 5 days on top of standard of care (SOC) compared with SOC alone, in patients with acute respiratory distress syndrome (ARDS) triggered by COVID-19.

Medienart:	Klinische Studie

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	WHO International Clinical Trials Registry Platform - (2023) vom: 09. Jan. Zur Gesamtaufnahme - year:2023

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: Acute respiratory distress syndrome caused by Covid-19 MedDRA version: 21.1Level: PTClassification code 10001052Term: Acute respiratory distress syndromeSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Phase: Phase 2 Recruitment Status: Not yet recruiting Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 11-11-2020, Last updated: 2023-01-13

ICTRP ID:	EUCTR2020-002913-16-DE 0135-0347 2020-002913-16-BE

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	WHO007582374

Internformat


LEADER	01000caa a22002652 4500
001	WHO007582374
003	DE-627
005	20230425182945.0
007	cr uuu---uuuuu
008	210512s2023 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)WHO007582374
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2020-002913-16-DE
035			\|a (UBBS_Klinische_Studien_WHO)0135-0347
035			\|a (UBBS_Klinische_Studien_WHO)2020-002913-16-BE
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a The TRISTARDS trial - ThRombolysIS Therapy for ARDS A study to test whether different doses of alteplase help people with severe breathing problems because of COVID 19. \|b The TRISTARDS trial - ThRombolysIS Therapy for ARDSA Phase IIb/III operationally seamless, open-label, randomised, sequential, parallel-group adaptive study to evaluate the efficacy and safety of daily intravenous alteplase treatment given up to 5 days on top of standard of care (SOC) compared with SOC alone, in patients with acute respiratory distress syndrome (ARDS) triggered by COVID-19.
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 11-11-2020, Last updated: 2023-01-13
650		4	\|a Medical Condition: Acute respiratory distress syndrome caused by Covid-19 MedDRA version: 21.1Level: PTClassification code 10001052Term: Acute respiratory distress syndromeSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 2
650		4	\|a Recruitment Status: Not yet recruiting
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2023) vom: 09. Jan.
773	1	8	\|g year:2023 \|g day:09 \|g month:01
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002913-16 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2023 \|b 09 \|c 01

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände